Gross Margin

A top financial forum is urging a GST hike, corporate tax cuts, and a radical revamp of retirement savings in its bold 2026 federal budget proposal.

MBX Biosciences prepares for the Jefferies conference, with investors eyeing updates on its late-stage hypoparathyroidism drug and promising obesity portfolio.

Tribe Property Technologies reports its second straight quarter of positive adjusted EBITDA, signaling a shift toward sustainable growth and tech-led consolidation.

MNTN's CEO faces investors at two key June conferences. Amid record profits and a competitive market, the stakes are high for the CTV ad-tech firm.

With booming revenue and a new premium product on the horizon, Grindr's CFO is set to outline the company's ambitious future to investors this month.

The JOi Dollar Plus operator is upsizing its convertible debt offering, signaling strong investor confidence and a strategic pivot to retire senior debt.

After unprecedented growth, Clear Fork Bank names a new CEO known for community ties, signaling a strategy to blend legacy values with future expansion.

NewGenIVF, a firm with roots in fertility and facing financial headwinds, is investing in a $100M AI startup. Is it a visionary pivot or a risky gamble?

Dream Finders Homes escalates its takeover attempt of Beazer Homes with a public offer, citing a decade of underperformance and a failing strategy.

With final court approval, Crescita Therapeutics will be delisted from the TSX as global platform ClinActiv snaps up its dermatology assets.

Celebrating a half-century of progress, Liberty Hill Foundation's anniversary gala was an urgent plea to fund the fight for Los Angeles's future.

CFO Martin Fischer's reappointment secures leadership continuity, reinforcing Fresenius Medical Care's focus on financial discipline and long-term growth.

Two iconic American brands partner to reclaim the spritz, blending Michigan cider and California bubbly for a new patriotic cocktail celebrating 250 years.

As Michigan homeowners face steep premium hikes, a new tech-driven insurer arrives, offering a data-centric model for agents and consumers.

Strong glaucoma sales and disciplined spending helped Iridex narrow its quarterly loss, signaling resilience despite retina segment woes and global headwinds.

Following a record year of profit and growth, the French diagnostics firm secures a major analyst endorsement, signaling a powerful turnaround. What's next?

With revenue hitting a record $47.6M, TerraCycle proves sustainability is profitable. But as it raises millions, can it overcome greenwashing critiques?

A top scientific honor for Dr. Mariano Garcia-Blanco validates a new approach to autoimmune disease, targeting a genetic trait in 50% of the population.

Newly public Yesway faces its first major test with its Q1 earnings. Investors will scrutinize if its aggressive expansion can meet high analyst expectations.

A $290M war chest fuels a new public biotech aiming to help millions of migraine patients who don't respond to current blockbuster therapies.